Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Oligodendroglial NMDA Receptors Regulate Glucose Import and Axonal Energy Metabolism.
Arzerra receives approval in Japan
Restoring immune tolerance in neuromyelitis optica: Part II.
Protocols for Cloning, Expression, and Functional Analysis of Sirtuin2 (SIRT2).
Four-dimensional flow magnetic resonance imaging and ultrasound assessment of cerebrospinal venous flow in multiple sclerosis patients and controls.
Pediatric acquired CNS demyelinating syndromes: Features associated with multiple sclerosis.
A multi-time-point modality-agnostic patch-based method for lesion filling in multiple sclerosis.
Neuromyelitis optica accompanied by nephrotic syndrome and autoimmune-related pancytopenia.
The Role of Obstructive Sleep Apnea in Cognitive Dysfunction in Multiple Sclerosis.
Specific immune complexes augment in vitro acetylcholine receptor-specific T-cell proliferation.
Favorable outcome of a pregnancy after fampridine exposition during the first month.
Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
Severe tumefactive rebound of multiple sclerosis following fingolimod cessation.
Transbulbar B-Mode Sonography in Multiple Sclerosis: Clinical and Biological Relevance.
Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis.
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.
Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies.
Herpes zoster laryngitis in a patient treated with fingolimod.
A mouse model for testing remyelinating therapies.
Treatment trials in progressive MS-current challenges and future directions.
Neuroprotection by central nervous system remyelination: Molecular, cellular, and functional considerations.
Reduced fecal GABA levels in multiple sclerosis patients.
Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting.
Major depressive disorder.
Pages
« first
‹ previous
…
709
710
711
712
713
714
715
716
717
…
next ›
last »